Industry Delighted By ‘Fixed’ USMCA
Removes Biologic Exclusivity Requirement And Allows Incentives For Generics
Executive Summary
Industry associations in the US and Canada have welcomed revisions to the proposed US-Mexico-Canada trade agreement that remove potentially damaging provisions around biologic data exclusivity and include measures favorable to generics, including incentives for generic competition.
You may also be interested in...
USMCA Passes Muster In US Senate
The US Senate’s vote to approve legislation underpinning the US-Mexico-Canada trade agreement has been welcomed by the country’s off-patent industry.
China Commits To Patent Linkage And Extensions In US Trade Deal
The first phase of a major trade agreement just signed by the US and China obliges the latter to implement a system linking pharma patent enforcement to marketing authorization procedures as well as to offer patent-term extensions.
China Commits To Patent Linkage And Extensions
The first phase of a major trade agreement just signed by the US and China obliges the latter to implement a system linking pharma patent enforcement to marketing authorization procedures as well as to offer patent-term extensions.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests:
